Vitafoods Insights is part of the divisionName Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Curcugen Pic.jpg

Next generation curcumin ingredient to be unveiled at Vitafoods Europe

The recently established Dolcas Tenshi Bioceuticals (DTB) unveils Curcugen™, the newest member to join its growing portfolio of nutraceuticals. Curcugen, inspired by the formulation’s 'next-generation' features, is a 100% natural, water-dispersible curcumin ingredient debuting at Vitafoods Europe in Geneva.

Curcugen’s patent-pending composition base is a novel-source turmeric oleoresin, rather than the 95% standardised curcuminoid material common in the supplement industry.  The SELF D™ platform technology optimizes the oleoresin base so that its benefits can be fully realized. Further, it avoids the need to complement the curcuminoids with other, non-turmeric ingredients, or reconstitute it with displaced turmeric ingredients.

In contrast to certain generic curcumin products, Curcugen’s unique formulation preserves the original complex of curcuminoids, essential oils, and polar resins within the optimized oleoresin  matrix. These naturally occurring constituents help to overcome the absorption issues characteristic of unformulated curcumin.Curcugen’s composition allows for optimised dispersion in beverage formats. In the GI tract, this provides an increased surface area of curcumin molecules, allowing greater contact with the intestinal lining. The product is among the most concentrated curcumin ingredients on the market—with curcuminoid concentrates at a 50% standard—and maintains a 95% turmeric rhizome base, free from chemical excipients.

Additional unique properties include a self-dispersing mechanism in liquid that allows for a clinical dose in a fluid medium, making it suitable for functional foods and ready-to-mix/RTD beverages. As a free-flowing dry ingredient, Curcugen offers multiple formulation options, including traditional capsules, gummies, soft chews and oral dispersible formats.

“We believe Curcugen’s comprehensive profile will generate significant interest and readily establish itself even in this crowded curcumin markets as it overcomes a number of limitations including delivery, potency, bioavailability and its clean-label appeal,” says Shavon Jackson-Michel, ND, Director of Medical & Scientific Affairs at Dolcas Tenshi Bioceuticals.

An extensive clinical study program for Curcugen evaluating safety and efficacy (including GRAS assessment) is being initiated regionally and internationally. The results of several such studies are expected to be published by the end of this year.

While the curcumin industry might appear saturated, recent evaluations of the market actually suggest an expanding market with the prospect of continued thriving growth of 5.5% per year, into at least 2024, according to research by Future Market Insights.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish